ShangPharma Corporation (SHP)
ShangPharma Corporation Debt to Equity Ratio: 0.00
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SHP Debt to Equity Ratio Rankings
| Overall | 99th percentile | 1 of 4262 |
| Sector | 99th percentile | 1 of 478 in Healthcare |
| Industry | 99th percentile | 1 of 146 in Biotechnology |
SHP Debt to Equity Ratio Range, Past 5 Years
| Minimum | 0.00 | Sep 2011 |
| Maximum | 0.0113 | Sep 2010 |
| Average | 0.0051 |
About Debt to Equity Ratio
YCharts Calculation: Debt to Equity = (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity
The debt to equity ratio is a leverage ratio indicating the relative proportion of shareholders' equity and debt used to finance a company's assets. It reveals how a company has financed its assets. A low debt to equity ratio indicates lower risk because shareholder's have claims on a larger portion of the company's assets.
A high debt to equity ratio usually means that a company has been aggressive in financing growth with debt and often results in volatile earnings.
It is also known as Debt/Equity Ratio, Debt-Equity Ratio, and D/E Ratio.
Learn More
You may also be interested in these SHP related companies
SHP News
ShangPharma to Report First Quarter 2012 Financial Results on May 17, 2012
May 03, 8:00AM PR Newswire
May 03, 8:00AM PR Newswire
ShangPharma Corp. (SHP) Misses Q4 EPS by 4c; Issues Light FY12 Revs Outlook
Mar 12, 6:53AM Street Insider
Mar 12, 6:53AM Street Insider
ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012
Feb 28, 8:00AM PR Newswire
Feb 28, 8:00AM PR Newswire
ShangPharma (SHP) Receives First Milestone in Research Partnership with Hengrui
Jan 19, 8:04AM Street Insider
Jan 19, 8:04AM Street Insider
ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui
Jan 19, 8:01AM Benzinga
Jan 19, 8:01AM Benzinga
ShangPharma Announces Opening of New Facility to Support Lilly's Pipeline
Jan 10, 8:00AM PR Newswire
Jan 10, 8:00AM PR Newswire
ShangPharma to Present at J.P. Morgan's 30th Annual Healthcare Conference
Dec 14, 8:00AM PR Newswire
Dec 14, 8:00AM PR Newswire
ShangPharma Corporation (SHP) Announces Resignation of Chief Operating Officer, Mr. Kevin Chen
Dec 12, 8:03AM Street Insider
Dec 12, 8:03AM Street Insider
ShangPharma to Report Third Quarter 2011 Financial Results on November 21, 2011
Nov 07, 8:00AM PR Newswire
Nov 07, 8:00AM PR Newswire
Just added a position with $SHP. Might not carry this overnight...will see what happens.
about 293 days ago by suPEARLative5
about 293 days ago by suPEARLative5
Market talk Astrazenca ($AZN LN) could be interested in Shire ($SHP LN) $$
about 408 days ago by RANsquawk
about 408 days ago by RANsquawk
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SHP | 6.43 | +0.05 | +0.78% | 119.11M |
| SHOR | 4.19 | +0.17 | +4.23% | 193.64M |
| SHOO | 40.48 | -0.09 | -0.22% | 1.785B |
| SHO | 10.00 | +0.20 | +1.99% | 1.168B |
| SHLO | 10.10 | +0.26 | +2.64% | 165.71M |
| SHLM | 21.36 | -0.32 | -1.48% | 637.61M |
| SHLD | 49.62 | -2.72 | -5.20% | 5.569B |
| SHIP | 2.29 | -0.02 | -0.87% | 27.39M |
| SHI | 28.65 | -0.35 | -1.21% | 884.50M |
| SCHW | 12.41 | -0.11 | -0.88% | 15.92B |
